
In this discussion, Dr. Paolo Tarantino reviews treatment selection and adverse-event management for patients with hormone receptor-positive, HER2-negative advanced breast cancer whose disease progresses after first-line CDK4/6 inhibitor plus endocrine therapy. He explains how clinical characteristics and tumor biology, including findings from tissue-based testing and circulating tumor DNA, can inform subsequent treatment decisions. Using a hypothetical patient with an activating AKT1 mutation, an ESR1 mutation, and baseline metabolic risk factors, Dr. Tarantino discusses the rationale for considering capivasertib plus fulvestrant and the importance of assessing glucose status before treatment. He outlines practical strategies for anticipating, monitoring, and managing hyperglycemia, diarrhea, cutaneous reactions, and stomatitis, including patient education, supportive medications, treatment interruption, and dose modification. The discussion also considers multidisciplinary care, differences in toxicity profiles across pathway-directed agents, and the limitations of indirect cross-trial comparisons. Throughout, Dr. Tarantino emphasizes individualized treatment decisions and proactive toxicity management to help patients maintain quality of life while benefiting from therapy.





























